23 xx 1Development of INCB33890 in collaboration with Merus. 25 1Source: Source: Wave 2 ATU fielded February 3 – March 2 Monjuvi sales up 11% Y/Y; continued growth in Community accounts (75% of total volume) Opzelura launch has outperformed other brands prescribed by dermatologists Atopic dermatitis and vitiligo patient relationship and support programs to help patients start and stay on therapy Treatment of choice in CCA and MLN for eligible patients in the U.S. Pemazyre launch is ongoing in 10 key markets ...

Incyte Corporation (NASDAQ:INCY) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants Christine Chiou - Head of Investor Relations Herve Hoppenot - President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager, North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Eva Privitera - TD Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Incyte Corporation (NASDAQ:INCY) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager-North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Dash Dhanak - Executive Vice President and Chief Scientific Officer Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State of other jurisdiction of in ...

官方 | W ■ == 00 00 10 100 Incyte 2022 Third Quarter Financial and Corporate Update NÖVEMBER 1, 2022 Forward-Looking Statements 2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including any discussion of the following: the growth potential of Incyte's oncology and dermatology franchises and the opportunities presented by Incyte's portfolio; expectations with respect to demand for and uptak ...

Incyte Corporation (NASDAQ:INCY) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager-North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Dash Dhanak - Executive Vice President and Chief Scientific Officer Co ...

Incyte Corporation (NASDAQ:INCY) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Christine Chiou – Head of Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and General Manager-North America Steven Stein – Executive Vice President and Chief Medical Officer Christiana Stamoulis – Executive Vice President and Chief Financial Officer Dash Dhanak – Executive Vice President and Chief Scientific Officer Co ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2022 Second Quarter | | | | | | | | | | Financial and Corporate Update AUGUST 2, 2022 | | | | | | | | | | | | | | | | | | | Forward-Looking Statements 2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimat ...

1 S286 Presented at the European Hematology Association (EHA) 2022 Hybrid Congress 9–17 June, 2022; Vienna, Austria (& Virtual) | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------| | | | | Long-Term Efficacy and Safety Results From an Ongoing | | | Open-Label Phase 2 Study of Parsaclisib for the | | | Treatment of Autoimmune Hem ...